Indian Pharmaceutical Supplier to Nepal.
Roughly four out of every five medicine packs imported into Nepal originate from India, and almost every working day a Mumbai-side pharma exporter is dispatching cargo through Birgunj or up the Tribhuvan air route. M Care has run the Nepal lane on INR settlement for years. If you are a hospital pharmacy buyer at Norvic, B&B or CIWEC, a DDA-registered importer, or a Department of Health Services tender desk reading the same Indian-supplier shortlist for the third year running, this page is the operational version.
DDA, the local-manufacturer tension, and the cross-border lane.
The Department of Drug Administration (DDA) under the Ministry of Health and Population is the single licensing gate for medicines in Nepal. DDA accepts WHO-GMP as the manufacturing-site standard and CDSCO Certificates of Pharmaceutical Product issued in WHO format. Indian manufacturers and Indian dossiers carry an informal recognition advantage at DDA that has been built up across two decades of bilateral trade.
Roughly 195 Nepalese importers hold DDA registration. Imports flow against a registered importer's licence, with per-product Marketing Authorisation valid for five years. The cross-border road route via Birgunj and Raxaul is the workhorse logistics pattern; Tribhuvan International (KTM) handles cold-chain and time-sensitive air consignments. Most pharma cargo clears Indian customs at Raxaul ICD and Nepal customs at Birgunj inside two to three working days for compliant CTD-backed shipments.
Two policy currents matter in 2026. First, Nepalese government policy has tilted toward supporting domestic manufacturing; local Nepali manufacturers now cover roughly 45 per cent of the market by volume and are growing. Imports remain dominant but the policy direction matters for bid pricing. Second, INR settlement under the SAARC trade framework continues to remove the FX-exposure friction that complicates Indian exports to other Asian markets. The Nepalese Rupee is pegged to the Indian Rupee at 1.6:1, and most invoices between Indian and Nepalese pharma counterparts settle in INR.
On the procurement side, the Department of Health Services (DoHS) runs central tenders for government hospitals; private hospitals (Norvic, B&B, CIWEC, Patan, Bir, Grande, Mediciti) procure independently from DDA-registered importers. Retail flows through pharmacy networks that work with multiple importers in parallel.
Call & WhatsApp the Mumbai desk: +91 70156 05768 · info@mcareexports.com · Mon–Sat 09:30–18:30 IST
Six fronts on the Nepal lane.
DDA Marketing Authorisation
End-to-end DDA Marketing Authorisation packs in CTD format, manufacturer site registration and per-product files. First-time generic registration runs 6 to 12 months from file submission to MA grant; renewals are quicker and benefit from the long bilateral track record.
Birgunj road freight
Mumbai to Birgunj road is the workhorse logistics pattern: 3 to 5 days door-to-door including Indian customs clearance at Raxaul ICD and Nepal customs at Birgunj. Suited to ambient palletised supply, generic injectables and the OTC retail backbone.
Tribhuvan air freight
BOM to KTM direct on Air India and Nepal Airlines, 3 hours wheels-up to wheels-down. Suited to cold-chain biologicals, ICU paralytics and emergency-supply scenarios. Validated Envirotainer and Pelican BioThermal lanes with Sensitech temperature logging.
INR settlement under SAARC trade
Standard pricing in INR on the Nepal lane. Settlement through SBI Nepal, NIC Asia, NABIL or HBL with documentation that matches the Nepalese importer's regulatory chain. No FX-exposure lag; faster cash-conversion than every other regional lane.
Private hospital chain supply
Norvic, B&B, CIWEC, Patan and Mediciti procurement runs on rolling forecasts where the volume justifies it. Cold-chain biologicals, oncology injectables, branded generics on private outpatient supply, weekly call-off where demand is steady.
DoHS tender response
Department of Health Services tenders for the WHO Essential Medicines List backbone, anti-TB, anti-malaria, EPI vaccines and the Free Health Care Programme drug list. Bid packs assembled in Mumbai to the DoHS template, typical turnaround 5 to 8 working days.
How stock actually arrives in Kathmandu Valley.
Nepal is the easiest international lane for an Indian pharma exporter, and that is not a marketing claim, it is the structural advantage that comes from a shared land border, an INR-pegged currency and twenty years of established bilateral trade. The default freight pattern depends on the cargo: ambient palletised supply moves by road via Mumbai to Birgunj, three to five days door-to-door, with Indian customs clearance at Raxaul ICD and Nepal customs at Birgunj typically completing inside two working days for compliant CTD-backed pharma cargo.
Cold-chain and time-sensitive cargo flies. The default air pattern is BOM to KTM direct on Air India or Nepal Airlines, three hours wheels-up to wheels-down. Dispatch cut-off at Mumbai is 14:00 IST for next-morning availability at Tribhuvan Cargo. Validated Envirotainer RKN e1 covers 2 to 8 degree celsius bulk; Pelican BioThermal Credo Cube and Sofrigam TPi handle smaller consignments. Continuous Sensitech temperature logging follows the consignment from Mumbai dispatch through to the receiving DDA-registered importer's warehouse in Kathmandu Valley, with data-files attached to the airway bill.
Commercial terms are unusually favourable for an international lane. INR invoicing is the default. First-time buyers settle by 50/50 advance and balance on delivery, or by documentary LC at sight where the importer's bank line supports it. From order two onwards, terms migrate to open account thirty days, with sixty and ninety-day terms opening up once the relationship and volumes settle. The combination of INR settlement, three-day road transit and DDA's bilateral recognition track makes Nepal the lowest-friction international pharma lane M Care runs.
Where Nepalese demand actually sits.
Nepal is a paediatric-heavy and rural-health-heavy formulary on the public-sector side, and a chronic-disease and specialty-injectable formulary on the private-hospital side. The DoHS Free Health Care Programme drug list and the broader EML coverage drive most state procurement: anti-infectives, anti-TB and anti-malaria, basic cardiovascular, basic diabetes, paediatric formulations and EPI vaccines.
Private hospital procurement looks different. Norvic, B&B, CIWEC and Mediciti run a chronic-disease and acute-care formulary close to a regional Indian tertiary hospital: oncology lines (paclitaxel, gemcitabine, oxaliplatin, biosimilars), cardiovascular (DOACs, the statin block, ACE inhibitors), diabetes (insulins and oral antidiabetics, with the analogue biosimilar bench growing), and the anti-infective shelf (carbapenems, glycopeptides, antifungals).
Cold-chain biologicals are the fastest-growing slice on both channels. Insulin analogues and oncology biosimilars run through validated Envirotainer lanes from Mumbai to Kathmandu. Anti-tuberculosis therapy is structurally important and runs on WHO-PQ-eligible product through donor-funded procurement. We hold capability across every category Nepal currently tenders, and are explicit on the categories where Nepalese local manufacturers now compete head-on at lower price points and we choose not to bid.
A Kathmandu Valley private hospital came to us in 2024 needing emergency supply on a fourth-generation cephalosporin when their existing wholesaler ran short. We identified a DDA-registered SKU from one of our Hyderabad partners, prepared the destination-language pack-insert variant and shipped a validated trial batch from Mumbai to Tribhuvan inside four working days. The hospital carried the molecule forward on a 12-month standing order at INR-denominated pricing, and added two further oncology lines once the cold-chain audit cleared. Stockout incidents in twelve months: zero.
Why M Care is the Nepalese desk's natural counterparty.
The structural case for sourcing from India is not a question in Nepal; the question is which Indian counterparty handles documentation that DDA actually accepts on first pass, settles in INR without ten-step bank routing, and runs the Birgunj road lane competently. M Care has been working that lane since our earliest export years. We have the bilateral-bank relationships, the DDA-fluent documentation team in Mumbai, and the road and air operations partners on both sides of the border.
What we do not do is over-promise on the categories where Nepalese local manufacturers now compete on price. Where the local industry is strong and growing, and the Nepalese government's domestic-manufacturing policy is tilting buyers toward local supply, we say so at the enquiry stage rather than bid into a losing position. Where an imported product is the right answer, the Mumbai desk delivers fast, on INR terms, with documentation matched to your DDA-registered importer's regulatory chain.
What Nepalese buyers ask us first.
Are your manufacturing partners DDA-registered for the Nepal market?
Yes, on every molecule we actively quote into Nepal. DDA accepts WHO-GMP as the manufacturing standard and routinely accepts CDSCO-issued Certificates of Pharmaceutical Product. We can provide the latest WHO-GMP inspection report, Site Master File extract and batch Certificate of Analysis ahead of any trial order so your QA lead and DDA file-holder can sign off before a purchase order is raised.
Do you settle in INR on the Nepal lane?
Yes. INR is the standard settlement currency on the Mumbai-Nepal pharma lane. Documentation runs through SBI Nepal, NIC Asia, NABIL or HBL depending on the importer's banking relationship. The Nepalese Rupee is pegged to the Indian Rupee at 1.6 to 1; there is no FX-exposure risk on standard trade timelines.
What is the lead time on a Mumbai to Kathmandu shipment?
Air via Air India or Nepal Airlines BOM-KTM direct: 36 to 48 hours door-to-door including airport clearance at Tribhuvan. Road via Birgunj: 3 to 5 days door-to-door with Indian customs clearance at Raxaul ICD and Nepal customs at Birgunj. Cold-chain on validated Envirotainer or Pelican BioThermal lanes with continuous Sensitech logging.
Can you supply both DoHS tenders and private hospital chains?
Yes. Department of Health Services tenders cover the WHO Essential Medicines List backbone and the Free Health Care Programme drug list; we bid these through DDA-registered importers in 5 to 8 working days. Private hospital chains (Norvic, B&B, CIWEC, Patan, Mediciti) procure independently and we supply that channel directly with adapted documentation packs.
How do you handle the Nepalese local-manufacturer competition?
We tell you at the enquiry stage where Nepalese local manufacturers now compete competitively on price. The Nepali domestic industry covers roughly 45 per cent of the market and is growing. On the categories where local supply is strong, we will not bid in a losing position. On the categories where Indian supply still offers cost or quality advantage, we deliver fast and price for the long-term relationship.
Do you supply WHO-PQ products into Nepal donor programmes?
Yes. Our manufacturing partners hold WHO Prequalification on selected anti-TB, anti-malarial, paediatric ARV and EPI vaccine SKUs. Supply runs through documented Q-channels into Global Fund, UNICEF and Gavi-routed Nepal programmes, with destination-language pack inserts and full chain-of-custody documentation.
Why Nepalese buyers choose M Care.
INR settlement, no FX friction
Standard INR invoicing through bilateral bank routing. SBI Nepal, NIC Asia, NABIL or HBL handle the documentation chain depending on the importer's banking relationship.
Birgunj or Tribhuvan, your choice
Road via Birgunj for ambient and palletised supply, 3 to 5 days door-to-door. Air via Tribhuvan for cold-chain and time-sensitive cargo, 36 to 48 hours door-to-door.
DDA-fluent documentation
CTD-format DDA filings backed by Indian WHO-GMP inspection reports and CDSCO CoPP. Bilateral recognition track means faster MA grants and smoother renewals than non-Indian counterparties experience.
Top categories we ship to Nepal
Anti-infectives
Penicillins, cephalosporins, carbapenems, anti-TB and anti-malarial regimens for DoHS and private supply.
Cardiovascular
Statins, ACE inhibitors, beta-blockers, DOACs and the heart-failure shelf.
Diabetes & endocrine
Insulins (human and analogue biosimilars), oral antidiabetics, thyroid therapy.
Oncology
Paclitaxel, gemcitabine, oxaliplatin, biosimilars and supportive-care lines for private hospital chains.
Respiratory
Inhalers, nebuliser solutions, ICS-LABA combinations — 117+ SKUs.
General & OTC
Analgesics, vitamins, wound-care, nutritionals for retail pharmacy networks.
Routes that sit behind the Nepal lane.
WHO-GMP compliance
Manufacturer registration and Site Master File support that DDA recognises on first pass under the bilateral track.
CTD dossier preparation
DDA-ready CTD dossiers from Indian WHO-GMP manufacturing sites; pack-insert variants where the molecule profile requires it.
Cold-chain validated supply
Validated 2 to 8 degree celsius lanes from Mumbai to Tribhuvan and onward to Kathmandu Valley with continuous logging.
Molecule, volume, ship-to. INR-priced, Mumbai-shipped.
Your enquiry goes directly to the account manager responsible for the Nepal desk. INR pricing on receipt; firm quote with documentation chain inside one working day.
Start a Nepal enquiry → Back to all markets